 Phase 1 study of FPI-1434 progressing towards multi-dose data and recommended Phase 2 dose in 1H2022 FPI-1966 advancing to clinic HAMILTON, ON and BOSTON, Aug. 10, 2021 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended June 30, 2021 and provided an update on clinical and corporate developments. We are building a fully integrated radiopharmaceutical company based upon our platform, reflecting a diverse pipeline of targeted alpha therapies in development supported by manufacturing and supply chain expertise, said Chief Executive Officer John Valliant, Ph.D. 